Engineered immune cells take on tough blood cancers in early trial
Disease control
Ongoing
This early-phase trial is testing a new treatment called MB-CART19.1 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better r…
Phase: PHASE1 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC